HOME >> BIOLOGY >> NEWS
Proteins in African HIV strains interact differently with drugs

Naturally occurring genetic variations in HIV-A and HIV-C, the two subtypes of HIV prevalent in Africa, make it harder for inhibitory drugs to bind to the protease, a key protein involved in viral maturation, according to a new report by biologists in The Krieger School of Arts and Sciences of The Johns Hopkins University.

Ernesto Freire, the Henry A. Walters professor of biology, emphasized that the new findings, published in The Proceedings of the National Academy of Sciences, are based on in-vitro tests of basic biochemical properties, and therefore cannot be used to assess the effectiveness of inhibitor drugs in patient treatments.

Instead, Freire suggested that the results add new support to the argument that scientists need to broaden the focus of HIV drug development, which has been almost exclusively centered on HIV-B.

"More than two-thirds of all AIDS cases today are in Africa, and those cases are predominantly HIV-A and HIV-C," says Freire. "Those different subtypes can vary genetically from the B subtype as much as 10 to 30 percent along their entire genome, and this new report proves that variation can affect interactions between drugs and HIV proteins at a very basic biochemical level. We need to broaden drug development efforts to include these subtypes."

For the research, Freire's group created recombinant forms of the proteases from HIV-A and HIV-C, using information from viral gene databases (GenBank) in Africa to recreate the proteins. HIV-A dominates in the northern part of Sub-Saharan Africa, while HIV-C is prevalent in southern regions.

Freire's lab measured the proteases' efficiency and biochemical fitness through factors related to catalysis, a chemical term for a process where one substance (the protease) accelerates a chemical reaction in another substance (the substrate) without being changed itself. The catalytic action of the protease is v
'"/>

Contact: Michael Purdy
mcp@jhu.edu
410-516-7160
Johns Hopkins University
13-May-2001


Page: 1 2

Related biology news :

1. Proteins show promise for mosquito control
2. Proteins transform DNA into molecular velcro
3. Proteins may help identify patients who will respond better to treatments in certain cancers
4. Proteins enable HIV to override cells defenses
5. New Science Press launches Proteins: From Sequence to Structure
6. Report: Proteins can be engineered as widely adaptable bioelectronic sensors
7. Proteins are vastly more complicated than previously realized
8. Life and death struggle: Proteins play against each other, bringing balance to immune system
9. Proteins that bind to sperm offer clues to male fertility and possible male contraception
10. Scientists Show Proteins Function Individually As Part Of DNA Repair
11. Genes Found That Label Cell Proteins For Disposal

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Proteins African HIV strains interact differently with drugs

(Date:5/21/2013)... occur in the body, stem cells in the ... differentiating into mature immune cells that can fight ... deplete these cell populations, potentially leading to the ... Now, a team of researchers led by biologists ... found that, in mouse models, the molecule microRNA-146a ...
(Date:5/21/2013)... University researchers have developed a new method for ... holes in the cell surface. The technique could ... related biological fields. , Bulk electroporation a ... reversible nanopores in the cell membrane that are ... is an increasingly popular method of cell transfection. ...
(Date:5/21/2013)... new University of Michigan Water Center today awarded ... Great Lakes restoration and protection efforts. , The ... diverse projects, including efforts to track the remediation ... techniques to control non-native weedy plant invasions; study ... fish responses to restoration activities. , The grants ...
Breaking Biology News(10 mins):Keeping stem cells strong 2Single-cell transfection tool enables added control for biological studies 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4
(Date:5/21/2013)... Wisc. (PRWEB) May 21, 2013 ... parts distributor , will be exhibiting for the ... Advancement of Medical Instrumentation (AAMI) 2013 Conference and ... purchase, support, distribute, and manufacture healthcare technologies. This ... in Long Beach, California. , The three-day ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... Canada (PRWEB) May 21, 2013 ... is a strong push within the industry to ... and Manufacturing Organizations and pharma companies often means ... frames. , Microtablets, developed in collaboration with Sensidose ... effective outsourcing can bring products to market sooner. ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: